New hope for tough blood cancers: experimental drug CG009301 enters human testing

NCT ID NCT07347171

First seen Jan 19, 2026 · Last updated May 13, 2026 · Updated 18 times

Summary

This early-phase study tests a new drug called CG009301 in adults with blood cancers (like leukemia or MDS) that returned or didn't respond to standard treatments. The main goals are to find a safe dose and check for side effects. About 45 participants will receive the drug until their disease gets worse.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • The First Affiliated Hospital of Nanchang University

    RECRUITING

    Nanchang, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • The Haematology Hospital of the Chinese Academy of Medical Sciences

    RECRUITING

    Tianjin, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Tongji Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology

    RECRUITING

    Wuhan, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.